These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26621480)

  • 1. Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop.
    Jarow JP; Ahmed HU; Choyke PL; Taneja SS; Scardino PT
    Urology; 2016 Feb; 88():8-13. PubMed ID: 26621480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    Gross MD; Sedrakyan A; Bianco FJ; Carroll PR; Daskivich TJ; Eggener SE; Ehdaie B; Fisher B; Gorin MA; Hunt B; Jiang H; Klein EA; Marinac-Dabic D; Montgomery JS; Polascik TJ; Priester AM; Rastinehad AR; Viviano CJ; Wysock JS; Hu JC
    J Urol; 2019 Nov; 202(5):952-958. PubMed ID: 31144591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop.
    Jarow JP; Thompson IM; Kluetz PG; Baxley J; Sridhara R; Scardino P; Carroll P; Albertsen P; Carter HB; Brawley O; Sartor O; Sandler H; Kiefert JJ; Morton RA
    Urology; 2014 May; 83(5):975-8. PubMed ID: 24661332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
    Lebastchi AH; George AK; Polascik TJ; Coleman J; de la Rosette J; Turkbey B; Wood BJ; Gorin MA; Sidana A; Ghai S; Tay KJ; Ward JF; Sanchez-Salas R; Muller BG; Malavaud B; Mozer P; Crouzet S; Choyke PL; Ukimura O; Rastinehad AR; Pinto PA
    Eur Urol; 2020 Sep; 78(3):371-378. PubMed ID: 32532513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.
    Jarow JP; Lerner SP; Kluetz PG; Liu K; Sridhara R; Bajorin D; Chang S; Dinney CP; Groshen S; Morton RA; O'Donnell M; Quale DZ; Schoenberg M; Seigne J; Vikram B
    Urology; 2014 Feb; 83(2):262-4. PubMed ID: 24332121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological control following partial gland ablation for intermediate-risk prostate cancer.
    Becher E; Lepor H
    Urol Oncol; 2020 Aug; 38(8):671-677. PubMed ID: 32487352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies.
    Golan R; Bernstein A; Sedrakyan A; Daskivich TJ; Du DT; Ehdaie B; Fisher B; Gorin MA; Grunberger I; Hunt B; Jiang HH; Kim HL; Marinac-Dabic D; Marks LS; McClure TD; Montgomery JS; Parekh DJ; Punnen S; Scionti S; Viviano CJ; Wei JT; Wenske S; Wysock JS; Rewcastle J; Carol M; Oczachowski M; Hu JC
    J Urol; 2018 Jun; 199(6):1488-1493. PubMed ID: 29307684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in urologic oncology 'OncoForum': The best of 2014.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp; 2015 Jun; 39(5):271-8. PubMed ID: 25770399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
    Weinstock C; Suzman D; Kluetz P; Baxley J; Viviano C; Ibrahim A; Jarow J; Sridhara R; Liu K; Carroll P; Eggener S; Hu JC; Hussain M; King M; Klein E; Kungel T; Makarov D; Pinto PA; Rini B; Roach M; Sandler H; Schlegel PN; Song D; Goldberg K; Pazdur R; Beaver JA
    J Urol; 2020 Jan; 203(1):115-119. PubMed ID: 31502940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low and Intermediate Risk Prostate Cancer: Oncologic and Functional Outcomes.
    Garcia-Barreras S; Sanchez-Salas R; Sivaraman A; Barret E; Secin F; Nunes-Silva I; Linares-Espinós E; Rozet F; Galiano M; Cathelineau X
    J Urol; 2018 Jan; 199(1):140-146. PubMed ID: 28823768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?
    Ong S; Chen K; Grummet J; Yaxley J; Scheltema MJ; Stricker P; Tay KJ; Lawrentschuk N
    BJU Int; 2023 Jan; 131(1):20-31. PubMed ID: 36083229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel focal therapy treatment options for prostate cancer.
    Werntz RP; Eggener SE
    Curr Opin Urol; 2018 Mar; 28(2):178-183. PubMed ID: 29232270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America.
    Touijer KA; Ahallal Y; Guillonneau BD
    Urol Oncol; 2013 Nov; 31(8):1517-21.e1-2. PubMed ID: 22687569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria.
    Secin FP; Bianco FJ; Cronin A; Eastham JA; Scardino PT; Guillonneau B; Vickers AJ;
    J Urol; 2009 Feb; 181(2):609-13; discussion 614. PubMed ID: 19084852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Hu JC; Basourakos SP; Futterer J
    Eur Urol; 2021 Feb; 79(2):167-169. PubMed ID: 33221091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
    Lowrance WT; Breau RH; Chou R; Chapin BF; Crispino T; Dreicer R; Jarrard DF; Kibel AS; Morgan TM; Morgans AK; Oh WK; Resnick MJ; Zietman AL; Cookson MS
    J Urol; 2021 Jan; 205(1):14-21. PubMed ID: 32960679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.